Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
Tectonic Therapeutic completes reverse merger with Avrobio, now trading on Nasdaq as Tectonic Therapeutic (TECX). The new company raised $130.7m in a private placement, ensuring cash reserves of $181m till mid-2027.